Identity and synonyms
Identity follows the supplied name and synonyms; no additional identity description is supplied.
Synonyms: ACTH(4–7)-PGP analogue
Peptide or peptide-related · Peptide or peptide derivative
Detailed molecular class: Synthetic peptide
Supplied sequence or chemical reference
See identity note; no supplier sequence accepted as verification.
Mechanism
Neurotrophic/BDNF-related hypotheses.
Evidence and critical reading
Reported scientific and empirical uses
Cognition and neurology
Handbooks describe focus, stress and neuroprotection. Post-stroke use, nootropic use and subcutaneous administration need separate evidence records.
Human evidence
Stroke-rehabilitation report is limited and not proof of healthy cognitive enhancement.
Preclinical evidence
Mechanistic and animal effects do not validate cognitive stacks.
Critical reading and limitations
The 110-patient study assessed BDNF and functional recovery in rehabilitation; its abstract does not establish a blinded placebo trial supporting generalization. A reported patient dose is not a basis for calculating a wellness regimen.
Evidence applies to the exact molecule, formulation, route, population and endpoint studied. Supplier identity, purity and clinical equivalence are unverified.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Human-study exposure
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Empirical handbook
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Reported by Peptide Handbook — James B. LaValle, Gordon Crozier, Joseph P. Cleaver and Andrew Heyman
300–1000 mcg · Amount per administration
- Frequency
- Source proposes daily or twice weekly.
- Duration
- Not stated on selected page.
- Route
- Subcutaneous
- Context
- Described neurological/nootropic use.
- Presentation
- Page also mentions nasal solutions; they are not treated as equivalent.
- Interpretation
- Does not validate efficacy or safety of this regimen; attributed to the handbook.
manual01 · Page 124 · October 16, 2026
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Reported by 2.pdf
250–1000 mcg · Amount per administration
- Frequency
- 1–2 times daily per source.
- Duration
- 10–30 days; 10–14-day break per source.
- Route
- Source mentions intranasal or SC without validating equivalence.
- Context
- Described focus/neuroprotection.
- Presentation
- Not stated on selected page.
- Interpretation
- Does not validate efficacy or safety of this regimen; attributed to the handbook.
manual07 · Page 42 · October 16, 2026
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Regulation and safety
Jurisdiction-specific regulatory context
US/EU authorization not established in reviewed official sources. Claims of Russian authorization require a current national record.
Adverse effects and unknowns
Long-term safety, psychiatric effects and interactions require better characterization. Modified analogues cannot inherit safety.
Contraindications
See supported safety statements and exact product label; a complete contraindication set has not been established for this catalog material.
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Only explicitly cited interactions may be asserted; unstudied combinations remain unknown, not interaction-free.
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
PMID29798983 · Clinical rehabilitation study
Rehabilitation after ischemic stroke.
Abstract reports daily amount; route not confirmed here.
BDNF and functional-recovery signals.
Allocation/blinding insufficiently described in abstract; do not extrapolate to healthy people.
n = 110
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
Semax · 0 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry querySource issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- PMID29798983
[The efficacy of semax in the tretament of patients at different stages of ischemic stroke].
Gusev EI, Martynov MY, Kostenko EV, Petrova LV, Bobyreva SN.
October 16, 2026
- R06
- R19
- manual01
Peptide Handbook — James B. LaValle, Gordon Crozier, Joseph P. Cleaver and Andrew Heyman
James B. LaValle; Gordon Crozier; Joseph P. Cleaver; Andrew Heyman
October 16, 2026
Bibliographic attribution only. The supplied handbook is a secondary empirical practice source, not clinical verification. Private source files and supplier/download destinations are not provided here.
- manual07
2.pdf
October 16, 2026
- pdf01
PEPNEXA 2.pdf
October 16, 2026
- pdf02
ELLA PEPTIDES.pdf
October 16, 2026
- pdf03
zlz list 26.8.5.pdf
October 16, 2026
- pdf05
PEPNEXA.pdf
October 16, 2026
- pdf07
US Peptide MangerCorp(1).pdf
October 16, 2026
- pdf09
PeptideFactory.pdf
October 16, 2026